Dual-therapy CD34 antibody-covered sirolimus-eluting COMBO stents versus sirolimus-eluting Orsiro stents in patients treated with percutaneous coronary intervention: the three-year outcomes of the SORT OUT X randomised clinical trial
Primary result · TLFResult — go to the resultIncidence rate ratio 1.33 95% CI 1.04–1.70Authors' conclusion
At 3 years, the SES was superior to the DTS, mainly because the DTS was associated with an increased risk of TLF within the first year but not from 1 to 3 years.
Study context
- Population
- All-comer patients treated with PCI
- Participants
- 3,146 patients
- Comparison
- DTS vs SES
- DTSn = 1,578
- SESn = 1,568reference
- Primary endpoint
- TLF: composite of cardiac death, MI or TLR
- Follow-up
- 3 years
Methodological detailsprospective, multicentre, registry-based follow-up
- Prospective
- Multicentre
- Registry-based follow-up
Primary result
TLF
Incidence rate ratio
1.33
95% CI 1.04–1.70
P = 0.02
Events by treatment group
DTS vs SES
IRR 1.33 (95% CI 1.04–1.70); P = 0.02
As reported in the abstract
Further findings
Target lesion failure (TLF) within first year
- Significantly higher TLF rate with DTS vs SES, mainly explained by higher target lesion revascularisation (TLR) incidence
TLF from 1 to 3 years
- TLF rates almost identical in both stent groups
Original publication
Dual-therapy CD34 antibody-covered sirolimus-eluting COMBO stents versus sirolimus-eluting Orsiro stents in patients treated with percutaneous coronary intervention: the three-year outcomes of the SORT OUT X randomised clinical trial. EuroIntervention. Published 23 October 2023. doi:10.
Summarised from the published abstract; every number is checked against it